34. [IF=6.9] Dongmei Qin et al."Lupeol improves bile acid metabolism and metabolic dysfunction-associated steatotic liver disease in mice via FXR signaling pathway and gut-liver axis."BIOMEDICINE & PHARMACOTHERAPY.2024 Aug;177:116942 33. [IF=5.4] Yingkun Sheng et al."Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway."JOURNAL OF ETHNOPHARMACOLOGY".2024 Apr;:118209 32. [IF=5.6] Dan Yang et al."Luteolin-β-CD-MOF prevents against acetaminophen-mediated liver damage by controlling ferroptosis through GSH/GPX4/SLC7A11 signal axis."Journal of Functional Foods".2024 May;116:106138 31. [IF=6.1] Shurui Zhang et al."Lactiplantibacillus plantarum ATCC8014 Alleviates Postmenopausal Hypercholesterolemia in Mice by Remodeling Intestinal Microbiota to Increase Secondary Bile Acid Excretion."JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY".2024;72(12):6236–6 30. [IF=4.9] Huang Hefei et al."Tanreqing injection inhibits dengue virus encephalitis by suppressing the activation of NLRP3 inflammasome."Chinese Medicine".2024 Dec;19(1):1-17 29. [IF=5.6] Shengyun Dai et al."Synergistic effect of Euphorbia kansui stir-fried with vinegar and bile acids on malignant ascites effusion through modulation of gut microbiota."Frontiers in Pharmacology.2023; 14: 1249910 28. [IF=3.9] Ya-nan Ou-Yang et al."High-salt diet induces dyslipidemia through the SREBP2/PCSK9 pathway in dahl salt-sensitive rats."BIOCHIMIE.2023 Oct;: 27. [IF=6.1] Sensen Chi et al."Time-restricted feeding alleviates metabolic implications of circadian disruption by regulating gut hormone release and brown fat activation."Food & Function.2023 Oct;: 26. [IF=7.9] Mei-Qi Wang et al."Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress."PHYTOMEDICINE.10.1016/j.phymed.2023.155124 25. [IF=4.6] Wei Li et al."Characterization of Metabolic Correlations of Ursodeoxycholic Acid with Other Bile Acid Species through In Vitro Sequential Metabolism and Isomer-Focused Identification."MOLECULES.2023 Jan;28(12):4801 24. [IF=4.212] Yingkun Sheng et al."PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes."Molecular Omics.2023 May;: 23. [IF=6.911] Yan-Zhen Wang et al."A strategy for screening and identification of new amino acid-conjugated bile acids with high coverage by liquid chromatography-mass spectrometry."ANALYTICA CHIMICA ACTA.2023 Jan;1239:340691 22. [IF=7.675] Lei Xu et al."Chenodeoxycholic Acid (CDCA) Promoted Intestinal Epithelial Cell Proliferation by Regulating Cell Cycle Progression and Mitochondrial Biogenesis in IPEC-J2 Cells."Antioxidants.2022 Nov;11(11):2285 21. [IF=4.571] Yuanjie Wen et al."The role of the farnesoid X receptor in quadruple anti-tuberculosis drug-induced liver injury."TOXICOLOGY.2022 Jun;476:153256 20. [IF=6.558] Yan Cao et al."Widely quasi-quantitative analysis enables temporal bile acids-targeted metabolomics in rat after oral administration of ursodeoxycholic acid."ANALYTICA CHIMICA ACTA. 2022 Jun;1212:339885 19. [IF=5.396] Juan Wu et al."Sargassum fusiforme polysaccharide is a potential auxiliary substance for metformin in the management of diabetes."Food Funct. 2022 Feb;: 18. [IF=3.935] Runjing Zhang et al."Xiaoyan lidan formula ameliorates α-naphthylisothiocyanate-induced intrahepatic cholestatic liver injury in rats as revealed by non-targeted and targeted metabolomics."J Pharmaceut Biomed. 2020 Feb;179:112966 17. [IF=3.935] Song Lin et al."A systemic combined nontargeted and targeted LC-MS based metabolomic strategy of plasma and liver on pathology exploration of alpha-naphthylisothiocyanate induced cholestatic liver injury in mice."J Pharmaceut Biomed. 2019 Jul;171:180 16. [IF=3.935] Song Lin et al."A systemic combined nontargeted and targeted LC-MS based metabolomic strategy of plasma and liver on pathology exploration of alpha-naphthylisothiocyanate induced cholestatic liver injury in mice."J Pharmaceut Biomed. 2019 Jul;171:180 15. [IF=5.34] Kaihui Zhang et al."A UPLC-MS/MS-based metabolomics analysis of the pharmacological mechanisms of rabdosia serra against cholestasis."Phytomedicine. 2021 Oct;91:153683 14. [IF=5.396] Cong Liang et al."Lactiplantibacillus plantarum H-87 prevents high-fat diet-induced obesity by regulating bile acid metabolism in C57BL/6J mice."Food Funct. 2021 May;12(10):4315-4324 13. [IF=5.396] Shiming Huang et al."A sulfated polysaccharide from Gracilaria Lemaneiformis regulates cholesterol and bile acid metabolism in high-fat diet mice."Food Funct. 2019 Jun;10(6):3224-3236 12. [IF=5.81] Shujing Lv et al."The Study on the Mechanism of Hugan Tablets in Treating Drug-Induced Liver Injury Induced by Atorvastatin."Front Pharmacol. 2021; 12: 683707 11. [IF=5.81] Li Peng et al."Detection of Vasodilators From Herbal Components by a Transcriptome-Based Functional Gene Module Reference Approach."Front Pharmacol. 2019 Oct;0:1144 10. [IF=3.935] Ziying Liu et al."Promotion of classic neutral bile acids synthesis pathway is responsible for cholesterol-lowing effect of Si-miao-yong-an decoction: Application of LC–MS/MS method to determine 6 major bile acids in rat liver and plasma."J Pharmaceut Bio 9. 曹妍,李婷,常安琪,蔣珍珍,于娟,屠鵬飛,宋月林.蛇膽中膽汁酸類化學成分分析[J].中國中藥雜志,2021,46(01):130-138. 8. 李瑋,蔣珍珍,李菡,屠鵬飛,宋青青,于娟,宋月林.利用在線加壓溶劑提取-超高效液相色譜-離子阱-飛行時間-質譜法定性分析片仔癀化學成分組[J].色譜,2021,39(05):478-487. 7. 曹妍, 宋青青, 李軍,等. 牦牛膽中膽汁酸類化學成分分析[J]. 中國中藥雜志 2019年44卷12期, 2538-2543頁, MEDLINE ISTIC PKU CSCD CA BP, 2019. 6. 陳云, 陳勁松, 郁紅禮,等. 膽南星發酵制品與混合蒸制品的鑒別研究[J]. 世界中醫藥, 2019, v.14(02):42-45+50. 5. 陳云 郁紅禮 吳皓 等. 發酵對膽南星中膽汁酸類成分的影響及膽南星中3種游離膽汁酸含量測定研究[J]. 中國中藥雜志 2018 43(22):99-103. 4. 陳江寧, 單國順, 劉曉瑜,等. 膽南星輔料成分分析及其清熱作用[J]. 中國現代中藥 2016年18卷7期, 837-840頁, ISTIC CA, 2016. 3. 席曉志, 李佳, 郭莎莎,等. 鵝去氧膽酸的大孔樹脂純化工藝優化及其降血脂活性[J]. 現代食品科技, 2018, 034(008):123-129. 2. 趙啟苗, 單國順, 陳江寧,等. 膽南星質量評價方法初探[J]. 中國實驗方劑學雜志, 2017(06):28-31. 1. 陳江寧 單國順 趙啟苗 等. 不同膽汁制膽南星中膽酸類成分及其解熱作用比較[J]. 現代藥物與臨床 2017 32(004):567-571.